Condition: Secondary Hyperparathyroidism · Sponsor: Amgen
Assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of etelcalcetide in the treatment of secondary hyperparathyroidism (SHPT) in pediatric participants between ≥ 2 to \< 18 years of age, with chronic kidney disease (CKD) on hemodialysis.
This description comes directly from the study's public registry record.
Amgen Call Center · 866-572-6436 · medinfo@amgen.com
Always discuss trial participation with your own doctor first.
| Universitair Ziekenhuis Gent | Ghent, Belgium | Terminated |
| Fakultni nemocnice v Motole | Prague, Czechia | Completed |
| Hospices Civils de Lyon Hopital Femme Mere Enfant | Bron, France | Terminated |
| Hopital Armand Trousseau | Paris, France | Completed |
| Kindernierenzentrum Bonn | Bonn, Germany | Completed |
| Universitaetsklinikum Koeln | Cologne, Germany | Recruiting |
| Universitaetsklinikum Hamburg Eppendorf | Hamburg, Germany | Recruiting |
| Medizinische Hochschule Hannover | Hanover, Germany | Completed |
| Universitaetsklinikum Heidelberg, Zentrum fuer Kinder und Jugendmedizin | Heidelberg, Germany | Recruiting |
| General Children Hospital Panagioti and Aglaias Kyriakou | Athens, Greece | Recruiting |
| Ippokrateio General Hospital of Thessaloniki | Thessaloniki, Greece | Recruiting |
| Semmelweis Egyetem | Budapest, Hungary | Terminated |
+ 11 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03969329